Navigation Links
Nanotechnology helps track and improve drug action in pancreatic cancer
Date:6/11/2013

UK and Australian scientists have been able to show ways in which we can markedly improve drug targeting of solid tumours, using tiny 'biosensors' along with new advanced imaging techniques.

In real time and in three dimensions, these technologies can show us how cancers spread and how active cancer cells respond to a particular drug. They can also tell us how much, how often and how long to administer drugs. Finally, using preclinical models of the disease, they can guide the use of 'combination therapies', techniques that enhance drug delivery by breaking up the tissue surrounding a tumour.

The study was performed by Dr Paul Timpson of the Garvan Institute of Medical Research and Professor Kurt Anderson of the Beatson Institute for Cancer Research in Glasgow, UK. PhD student Max Nobis studied the signaling protein 'Src', which becomes activated to drive invasive pancreatic cancer, and looked at how it could best be deactivated by a small molecule inhibitor currently in phase II clinical trials known as 'dasatinib'. Their findings are published in the journal Cancer Research, now online.

"We have already shown that Src is activated in pancreatic tumours and we knew that dasatinib deactivates Src and could partially reduce the spread of this form of cancer. Through a collaborative partner in the US, we had access to FRET (Fluorescence Resonance Energy Transfer) imaging technology," said Dr Paul Timpson.

"Until now, we have been limited to studying tumour signalling in two dimensions and lacked a dynamic way of reporting on drug targeting in live tumour tissue. Nanotechnology opens up a portal into living tissue that allows us to watch cancers spreading, and to determine which parts of a tumour we should be targeting with drugs."

"This imaging technology has allowed us to map areas within the tumour that are highly aggressive, allowing us to pinpoint regions of poor drug delivery deep within a tumour at sub-cellular resolution. We can then see where we need to improve on drug delivery to improve clinical outcome."

It has been hard to treat pancreatic tumours because they are extremely dense with collagen and have poor blood vessel networks for delivering drugs.

Professor Kurt Anderson observed that combination therapies can now be used to break down collagen, weakening tumour architecture and making it easier to get the drugs where they need to be. "The trick is to break down the structure just enough to get the drug in, but not so much that you damage the organ itself," he said.

"These new FRET technologies help us gauge what is just enough and not too much."

"These are very exciting discoveries we now have spatial and temporal information about cancer behaviour that we've never had before, as well as the nanotechnology to monitor and improve drug delivery in hard to reach tumour regions."


'/>"/>

Contact: Alison Heather
a.heather@garvan.org.au
61-292-958-128
Garvan Institute of Medical Research
Source:Eurekalert

Related biology news :

1. Purdue professor to speak before Congress about nanotechnology in brain treatment research
2. New study shows how nanotechnology can help detect disease earlier
3. Nanotechnology breakthrough could dramatically improve medical tests
4. Understanding the biological and ecological implications of safe nanotechnology
5. New study shows promise in using RNA nanotechnology to treat cancers and viral infections
6. Realizing the promise of RNA nanotechnology for new drug development
7. Mercury in water, fish detected with nanotechnology
8. European boost for DNA nanotechnology
9. Global Market for Nanotechnology to Reach $3.3 Trillion by 2018
10. Nanotechnology drug delivery shows promise for treatment of pediatric cancer
11. Bioengineer studying how to send drugs to lungs through nanotechnology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2018)... ... November 27, 2018 , ... ... have worked together to integrate the LabArchives Classroom Edition with Current Protocols Essential ... will be available beginning January of 2019. , The integration of ...
(Date:11/20/2018)... (PRWEB) , ... November 19, 2018 , ... ... by Applications (academic research tools, drug development, agriculture, human clinical therapeutics, and animal ... breeding products), by Technology (drug compound and target screening, and agriculture and industrial ...
(Date:11/20/2018)... ... November 20, 2018 , ... Like many large breed dogs, Jack, a ... was a year old, his mom, Rebecca, noticed he was slow to get up ... veterinarian and her suspicions were confirmed: Jack had bilateral hip dysplasia, a congenital condition ...
Breaking Biology News(10 mins):
(Date:11/6/2018)... ... November 06, 2018 , ... Crucial ... trial data collection and management. TrialKit ™, an eClinical platform, has incorporated ... can quickly and easily sign in to the app via facial recognition or ...
(Date:11/5/2018)... ... November 05, 2018 , ... GlycoMark, Inc., ... healthcare professionals through its website, http://www.glycomark.com , as part of National Diabetes ... video option via the website in November from 9 a.m. – 5 p.m. ...
(Date:11/3/2018)... (PRWEB) , ... November 01, 2018 , ... Triangle Insights ... Inc. Magazine as one of the fastest-growing private companies in the United States, appearing ... 5000 list ranks private companies based on percentage revenue growth over the previous three ...
(Date:10/31/2018)... ... ... young Labrador retriever. Like most labs, Pippa is energetic, crazy, and fun-loving. When ... in her right knee. According to her mom, Kinsley, Pippa was limping constantly and ... heart to see Pippa lie around in pain because it hurt too much to play. ...
Breaking Biology Technology: